PureSEQ MP

PureSEQ MP

Price range: $125.00 through $7,450.00

PureSEQ MP offers simple, rapid dye terminator removal for Sanger Sequencing. A superior CleanSEQ® replacement with no protocol changes.

Add to Wishlist
Categories: , SKU: P-3005 Tag:

Available Options:

Description

Product Details

PureSEQ MP utilizes proprietary paramagnetic bead technology for the highly effective removal of dye terminators, primer-dimers, salts, and nucleotides. As the most advanced solution in our dye terminator removal line, it serves as a superior replacement for Beckman Coulter’s CleanSEQ®.

PureSEQ MP provides enhanced purification efficiency for traditional Sanger Sequencing workflows. This drop-in replacement requires no protocol changes while delivering additional benefits, such as longer read lengths and high signal inensity. This simple, scalable procedure ensures high-quality results for both manual and automated high-throughput processing.

Key Features

  • Longer reads with High QV Scores close to 1,000 bp
  • Suitable for a wider range of DNA template concentrations including low concentration DNA templates
  • Even lower repeat rate with a pass rate of over 90% 
  • 384 and 96-well formatting usable; especially geared towards 384 well format
  • Designed to directly replace CleanSEQ with an additional feature of eliminating “GC” n+1 peaks

Data Sheet
View here.

PureSEQ Eletropherogram

pureseq figure 1
pureseq fig2

 

*CleanSEQ is a trademark of Beckman Coulter. BigDye is a trademark of Applied Biosystems.

Sizes:

  • 5 mL, 600 - 1,000 reactions
  • 50 mL, 5,200- 1,000 reactions
  • 250 mL, 25,000 - 50,000 reactions
  • Bulk; largest size

Storage:

  •  Store at 4°C upon arrival
  • AVOID FREEZING

Stability:

  • 12 months if stored as specified

 

Disclaimer: For research use only. Not for use in diagnostic procedures.

Protocols and SDS

Follow Aline's standard protocol below or use CleanSEQ® protocol with zero changes required.

Protocol-PureSEQ v2.3

SDS-PureSEQ-MP

Data Sheet

PureSEQ-MP Data Sheet

 

Product References in Journals

  1. Anderson, R. T., et al. Molecular cancer therapeutics, 12(10), 1994–2005. (2013). The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
    https://doi.org/10.1158/1535-7163.MCT-13-0206

Related products